The present invention is directed to a new class of triazine derivatives as described by formula I below in which A, X, R
1
, R
2
, R
3
, and R
4
are as defined herein and to the use of the compounds as PDE10 inhibitors.
Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues
申请人:Gao Yang
公开号:US20070232591A1
公开(公告)日:2007-10-04
Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues of the Formula:
are provided, in which variables are as described herein. Such compounds may be used to modulate ligand binding to histamine H3 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) and other disorders in humans, domesticated companion animals and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting histamine H3 receptors (e.g., receptor localization studies).
PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES
申请人:Gao Yang
公开号:US20110082130A1
公开(公告)日:2011-04-07
Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues of the Formula:
are provided, in which variables are as described herein. Such compounds may be used to modulate ligand binding to histamine H3 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) and other disorders in humans, domesticated companion animals and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting histamine H3 receptors (e.g., receptor localization studies).